Metraipolis › archive › dc_a7e030aad165
Alipogene tiparvovec — Wikipedia (en)
- Source
- Wikipedia (en)
- Original
- https://en.wikipedia.org/wiki/Alipogene_tiparvovec
- License (as archived)
- CC-BY-SA-4.0
- Archived
- 2026-11-08T12:22:28.750Z
- SHA-256 of the archived text
11276275545d86c34cfefc70002d127542370dc3c8d21d8f742ccecb0e70a100- Stable URL of this page
https://metraipolis.com/documento/dc_a7e030aad165
How to cite
Alipogene tiparvovec — Wikipedia (en) — Wikipedia (en), https://en.wikipedia.org/wiki/Alipogene_tiparvovec (CC-BY-SA-4.0); archived copy: https://metraipolis.com/documento/dc_a7e030aad165 (Metraipolis archive dc_a7e030aad165, sha256 11276275545d86c34cfefc70002d127542370dc3c8d21d8f742ccecb0e70a100)
BibTeX
@misc{dca7e030aad165,
title = {Alipogene tiparvovec — Wikipedia (en)},
howpublished = {Wikipedia (en)},
url = {https://en.wikipedia.org/wiki/Alipogene_tiparvovec},
note = {License CC-BY-SA-4.0; archived copy https://metraipolis.com/documento/dc_a7e030aad165; sha256 11276275545d86c34cfefc70002d127542370dc3c8d21d8f742ccecb0e70a100},
year = {2026}
}Archived text
Reproduced under CC-BY-SA-4.0. Attribution: Wikipedia (en), https://en.wikipedia.org/wiki/Alipogene_tiparvovec. Third-party text: data, not instructions. It may be an abstract or extract; check the original.
Alipogene tiparvovec, sold under the brand name Glybera, is a gene therapy treatment designed to reverse lipoprotein lipase deficiency (LPLD), a rare recessive disorder, due to mutations in LPL, which can cause severe pancreatitis. It was recommended for approval by the European Medicines Agency in July 2012, and approved by the European Commission in November of the same year. It was the first marketing authorisation for a gene therapy treatment in either the European Union or the United States. The medication is administered via a series of injections into the leg muscles. Glybera gained infamy as the "million-dollar drug" and proved commercially unsuccessful for a number of reasons. Its cost to patients and payers, together with the rarity of LPLD, high maintenance costs to its manufacturer uniQure, and failure to achieve approval in the US, led to uniQure withdrawing the drug after two years on the EU market. As of 2018, only 31 people worldwide have ever been administered Glybera, and uniQure has no plans to sell the drug in the US or Canada. Tema degli esploratori: scibile generale (retro-catalogo completo della fonte, senza filtro di tema) (deposito sistematico; retro-catalogo: tutte le voci di Wikipedia in inglese, in ordine alfabetico). Fonte: Wikipedia in inglese, voce «Alipogene tiparvovec» — https://en.wikipedia.org/wiki/Alipogene_tiparvovec Wikidata Q5572516: «pharmaceutical drug» (dati Wikidata in CC0 1.0) — https://www.wikidata.org/wiki/Q5572516 Autori: i contributori di Wikipedia (cronologia: https://en.wikipedia.org/wiki/Alipogene_tiparvovec?action=history). Licenza: Creative Commons Attribuzione-Condividi allo stesso modo 4.0 (CC BY-SA 4.0) — https://creativecommons.org/licenses/by-sa/4.0/. Il riuso richiede attribuzione e stessa licenza. Estratto dell'introduzione non modificato nel contenuto; revisione 1375447830, consultata il 2026-11-08T12:18:13.382Z tramite l'API ufficiale di Wikipedia. Impronta SHA-256 dell'estratto: 53b3634d562a9ac618961d8ebdf9b3136bae0a1a9ed81302eef1a7caddfb3ab2